Human Immunodeficiency Virus Therapeutics Market Size, Share, Trends, Growth Outlook

Human Immunodeficiency Virus Therapeutics Market is estimated to increase at a growth rate of 4.6% CAGR over the forecast period from 2024 to 2030.

The Human Immunodeficiency Virus Therapeutics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug (Branded Drugs, Generic Drugs), By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists).

An Introduction to Human Immunodeficiency Virus Therapeutics Market in 2024

The Human Immunodeficiency Virus (HIV) Therapeutics market in 2024 is experiencing significant advancements in antiretroviral therapies, preventive interventions, and treatment strategies aimed at managing HIV infection and improving patient outcomes worldwide. HIV remains a major global health challenge, with millions of individuals living with HIV/AIDS and millions more at risk of infection. The market offers a diverse range of antiretroviral drugs, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, and entry inhibitors, which target different stages of the HIV lifecycle and suppress viral replication. Moreover, with a focus on personalized medicine and precision therapies, the market is witnessing the development of novel treatment approaches such as long-acting injectable drugs, antibody-based therapies, and gene editing techniques to address viral resistance, treatment adherence, and HIV cure research. Additionally, with advancements in HIV prevention strategies, including pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and behavioral interventions, the market is expanding to include preventive interventions aimed at reducing HIV transmission rates and curbing the spread of the virus. As the global health community continues to work towards ending the HIV/AIDS epidemic, the HIV therapeutics market is poised for continued innovation, collaboration, and investment in research and development efforts aimed at achieving universal access to HIV prevention, treatment, and care services, and improving the quality of life for individuals affected by HIV/AIDS.

Human Immunodeficiency Virus Therapeutics Market Trend: Advancements in Antiretroviral Therapy

A prominent trend in the Human Immunodeficiency Virus (HIV) therapeutics market is the continuous advancements in antiretroviral therapy (ART). Over the years, there has been significant progress in the development of novel antiretroviral drugs, combination therapies, and treatment regimens for HIV infection. These advancements have led to improved efficacy, tolerability, and safety profiles of HIV medications, allowing for better disease management, reduced pill burden, and enhanced adherence to treatment. Additionally, innovations such as long-acting injectable formulations and once-daily single-tablet regimens have simplified HIV treatment regimens and improved patient convenience. This trend reflects the ongoing commitment to enhancing the quality of life and clinical outcomes for individuals living with HIV/AIDS.

Human Immunodeficiency Virus Therapeutics Market Driver: Rising Global Prevalence of HIV/AIDS

A key driver in the Human Immunodeficiency Virus (HIV) therapeutics market is the rising global prevalence of HIV/AIDS. Despite efforts to prevent new HIV infections and improve access to treatment and care, HIV/AIDS remains a significant public health challenge worldwide. The increasing number of people living with HIV/AIDS drives demand for effective antiretroviral therapy, opportunistic infection prophylaxis, and supportive care interventions. Furthermore, the persistence of high HIV transmission rates, particularly in low- and middle-income countries, underscores the need for continuous research and development of innovative HIV therapeutics to address evolving treatment needs, drug resistance, and emerging challenges in HIV/AIDS management.

Human Immunodeficiency Virus Therapeutics Market Opportunity: Development of Long-Acting Antiretroviral Drugs

An opportunity for growth in the Human Immunodeficiency Virus (HIV) therapeutics market lies in the development of long-acting antiretroviral drugs. Long-acting formulations offer the potential to improve treatment adherence, reduce treatment fatigue, and enhance treatment outcomes by providing sustained drug levels over extended dosing intervals. Long-acting antiretrovirals, such as injectable formulations or implantable devices, offer convenience and flexibility for patients who may struggle with daily pill regimens or face barriers to adherence. Additionally, long-acting therapies have the potential to address challenges associated with drug resistance, treatment failure, and viral rebound, thereby improving viral suppression rates and reducing the risk of HIV transmission. By investing in the research and development of long-acting antiretroviral drugs, pharmaceutical companies can capitalize on this opportunity to enhance treatment options and improve the quality of life for individuals living with HIV/AIDS. This opportunity aligns with the industry's focus on innovation, patient-centered care, and addressing unmet needs in HIV therapeutics.

Human Immunodeficiency Virus Therapeutics Market Segmentation

By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Human Immunodeficiency Virus Therapeutics Market Companies

AbbVie Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc
Genentech Inc
Gilead Sciences Inc
Merck & Co. Inc
ViiV Healthcare

 

 

Reasons to Buy the Human Immunodeficiency Virus Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Human Immunodeficiency Virus Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Human Immunodeficiency Virus Therapeutics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Human Immunodeficiency Virus Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Human Immunodeficiency Virus Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Human Immunodeficiency Virus Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Human Immunodeficiency Virus Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Human Immunodeficiency Virus Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Human Immunodeficiency Virus Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Human Immunodeficiency Virus Therapeutics Market Industry
4.2 Key Market Trends in Human Immunodeficiency Virus Therapeutics Market Industry
4.3 Potential Opportunities in Human Immunodeficiency Virus Therapeutics Market Industry
4.4 Key Challenges in Human Immunodeficiency Virus Therapeutics Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Human Immunodeficiency Virus Therapeutics Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Human Immunodeficiency Virus Therapeutics Market Outlook By Segments
7.1 Human Immunodeficiency Virus Therapeutics Market Outlook by Segments
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

8 North America Human Immunodeficiency Virus Therapeutics Market Analysis And Outlook To 2030
8.1 Introduction to North America Human Immunodeficiency Virus Therapeutics Markets in 2024
8.2 North America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Human Immunodeficiency Virus Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

9 Europe Human Immunodeficiency Virus Therapeutics Market Analysis And Outlook To 2030
9.1 Introduction to Europe Human Immunodeficiency Virus Therapeutics Markets in 2024
9.2 Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook By Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

10 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Human Immunodeficiency Virus Therapeutics Markets in 2024
10.2 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Human Immunodeficiency Virus Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

11 South America Human Immunodeficiency Virus Therapeutics Market Analysis And Outlook To 2030
11.1 Introduction to South America Human Immunodeficiency Virus Therapeutics Markets in 2024
11.2 South America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Human Immunodeficiency Virus Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

12 Middle East And Africa Human Immunodeficiency Virus Therapeutics Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Human Immunodeficiency Virus Therapeutics Markets in 2024
12.2 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc
Genentech Inc
Gilead Sciences Inc
Merck & Co. Inc
ViiV Healthcare

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists